Total assets contracted roughly 20% from $269.6M in 2024Q2 to $216.8M in 2026Q3, with cash of $15.3M and total debt of $2.5M leaving a debt-to-equity ratio of 0.01 that reflects a fully equity-funded structure.
Design Therapeutics, Inc. (DSGN) balance sheet — 7-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Total Current Assets | 213.96M | 223.78M | 248.04M | 284.58M | 335.12M | 385.44M | 36.23M | 90K |
| Cash & Short-Term Investments | 208.61M | 219.84M | 245.48M | 281.8M | 330.39M | 384.06M | 36.09M | 77K |
| Cash Only | 15.25M | 16.86M | 22.56M | 21.2M | 26.5M | 298.57M | 2.38M | 77K |
| Short-Term Investments | 193.36M | 202.99M | 222.91M | 260.6M | 303.89M | 85.5M | 33.71M | 0 |
| Accounts Receivable | 1.74M | 1.68M | 1.26M | 1.43M | 1.11M | 110K | 10K | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 25K | 8K |
| Total Non-Current Assets | 2.85M | 2.42M | 4.05M | 5.06M | 6.02M | 5.12M | 283K | 0 |
| Property, Plant & Equipment | 2.85M | 2.42M | 3.63M | 4.63M | 5.56M | 5.12M | 71K | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 427K | 430K | 459K | 0 | 212K | 0 |
| Total Assets | 216.81M | 226.2M | 252.09M | 289.64M | 341.14M | 390.56M | 36.52M | 90K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | 0.01x |
| Asset Growth % | -14.33% | -10.27% | -12.96% | -15.09% | -12.65% | 969.55% | 40473.33% | - |
| Total Current Liabilities | 12.75M | 13.05M | 8.46M | 9.62M | 10.78M | 5.28M | 2.33M | 3.73M |
| Accounts Payable | 2.08M | 2.31M | 2.19M | 1.94M | 3.02M | 1.62M | 1.4M | 2.48M |
| Days Payables Outstanding | - | - | - | 1.32K | 2.37K | - | 102.13K | 547.06K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 695K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 201K |
| Other Current Liabilities | 0 | 4.63M | 3.58M | 4.03M | 3.54M | 2.15M | 565K | 112K |
| Current Ratio | 16.78x | 17.14x | 29.31x | 29.58x | 31.10x | 72.96x | 15.55x | 0.02x |
| Quick Ratio | 16.78x | 17.14x | 29.31x | 29.58x | 31.10x | 72.96x | 15.55x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.86M | 645K | 1.53M | 2.33M | 3.05M | 3.14M | 45.5M | 1K |
| Long-Term Debt | 0 | 645K | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 6.73M | 0 | 1.53M | 2.33M | 3.05M | 3.14M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 45.5M | 1K |
| Total Liabilities | 14.61M | 13.7M | 10M | 11.96M | 13.83M | 8.43M | 47.83M | 3.73M |
| Total Debt | 2.51M | 1.53M | 2.33M | 3.05M | 3.69M | 3.63M | 0 | 695K |
| Net Debt | -12.74M | -15.32M | -20.23M | -18.15M | -22.81M | -294.94M | -2.38M | 618K |
| Debt / Equity | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | - | - |
| Debt / EBITDA | -0.03x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.16x | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | 202.2M | 212.5M | 242.1M | 277.69M | 327.31M | 382.13M | -11.31M | -3.64M |
| Equity Growth % | -20.56% | -12.22% | -12.82% | -15.16% | -14.35% | 3477.2% | -210.68% | - |
| Book Value per Share | 3.21 | 3.71 | 4.28 | 4.96 | 5.88 | 8.32 | -0.42 | -0.13 |
| Total Shareholders' Equity | 202.2M | 212.5M | 242.1M | 277.69M | 327.31M | 382.13M | -11.31M | -3.64M |
| Common Stock | 6K | 6K | 6K | 6K | 6K | 6K | 1K | 1K |
| Retained Earnings | -355.1M | -297.01M | -227.21M | -177.63M | -110.76M | -47.46M | -11.92M | -3.64M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -451K | 0 |
| Accumulated OCI | -1.68M | 403K | 475K | 62K | -3.36M | -244K | 156K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying DSGN stock.
As of 2025, Design Therapeutics, Inc. (DSGN) had total assets of $226.2M including $223.8M in current assets.
Design Therapeutics, Inc. (DSGN) carries total debt of $1.5M, offset by $219.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Design Therapeutics, Inc. (DSGN) has total shareholders' equity (book value) of $212.5M ($3.71 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Design Therapeutics, Inc. (DSGN) reported a current ratio of 17.14x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Limited cash runway against burn
Metrics are mathematically derived from official filings.
Shrinking Asset Base Signals Weakening Position
According to the reported balance sheets, DSGN's total assets declined from $269.6M in 2024Q2 to $216.8M in 2026Q3, a roughly 20% contraction that reflects steady cash consumption rather than any asset-building investment.
The decline in total assets is driven almost entirely by cash depletion, with reported cash falling from $45.7M to $15.3M over the period, which suggests the balance sheet is being run down to fund ongoing development. Shareholders' equity has eroded in parallel, and the accumulated deficit has grown from -$200.5M to -$355.1M, indicating that each quarter's operating losses are permanently reducing the capital base. Investors should view this trajectory as a weakening balance sheet whose strength depends on the timing of the next financing event.
Cash Reserves Thin Relative to Quarterly Burn
Based on reported figures, DSGN held $15.3M in cash at 2026Q3 against free cash flow of roughly -$15.4M in the same quarter, implying cash coverage of about one quarter of current burn.
The current ratio of 16.78 looks comfortable on paper, but it reflects a small liability base rather than a meaningful cash cushion, since the cash balance alone is nearly fully absorbed by a single quarter of operating outflows. The reported cash figure has also fallen in several recent quarters, suggesting the runway is shortening rather than stabilizing. Investors should treat the liquidity position as tight and monitor whether an equity raise or other financing is disclosed before the next reporting period.
Equity Base Eroding Through Accumulated Losses
As reported in the balance sheets, DSGN's equity fell from $261.2M in 2024Q2 to $202.2M in 2026Q3, with retained earnings deficits of -$355.1M absorbing essentially all paid-in capital growth.
Because the company reports no buybacks or dividends and carries a debt-to-equity ratio of only 0.01, the equity decline is a direct function of accumulated operating losses rather than capital returns or leverage effects. The stock-based compensation reported on the income statement partially offsets cash burn but also contributes to dilution over time. Investors should weigh whether future equity issuance, which appears necessary given the cash position, will further dilute existing holders.
Minimal Leverage Reflects Equity-Funded Model
According to reported figures, DSGN carries total debt of $2.5M against $202.2M in equity, a debt-to-equity ratio of 0.01 that indicates development is funded almost entirely through equity rather than borrowing.
The low leverage removes near-term refinancing risk, but it also means the company has no debt capacity to fall back on if equity markets tighten, since its cash-generating ability is negative. The modest debt balance appears to be lease or equipment related rather than a material financing obligation, though its composition is not detailed in the supplied data. Investors should recognize that the lack of debt is a function of the business model rather than a sign of balance sheet strength.
Reported Cash Figures May Understate Urgency
Because the supplied data lacks a current cash balance beyond the 2026Q3 figure, the reported $15.3M may not reflect the most recent liquidity position, and the analysis here rests on a potentially dated snapshot.
If cash reserves have declined further after the latest reported quarter, the runway implied by a single quarter of burn would be even shorter than the figures suggest. Conversely, undisclosed financing arrangements, collaboration payments, or non-dilutive funding could extend the runway, though none are reflected in the provided data and their existence cannot be assumed. Investors should verify current cash and any subsequent financing before drawing firm conclusions about survival timelines.